Correspondence re: Y. S. Haviv, J. L. Blackwell, A. Kanerva, P. Nagi, V. Krasnykh, I. Dmitriev, M. Wang, S. Naito, X. Lei, A. Hemminki, D. Carey, and D. T. Curiel, Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors. Cancer Res., 62: 4273-4281, 2002.
作者： Egbert Oosterwijk , Dorien M. Tiemessen , Peter F. A. Mulders , Wim Jongmans
DOI:
关键词: Biology 、 Cancer research 、 Retargeting 、 Receptor 、 Genetic enhancement 、 Cancer
摘要: In their article, Haviv et al. [(1)][1] suggested that gene therapy for renal cancer with the conventional serotype 5 adenoviral vectors is limited due to a deficiency in expression of CAR [1][2] on RCC cells. Subsequently, they and described use alternative
ru.nl
aacrjournals.org参考文章(2)
Adenoviral Gene Therapy for Renal Cancer Requires Retargeting to Alternative Cellular Receptors Cancer Research. ,vol. 62, pp. 4273- 4281 ,(2002) , 10.1016/S1525-0016(16)44194-8
Delphine Rea, Frederik H. E. Schagen, Rob C. Hoeben, Majid Mehtali, Menzo J. E. Havenga, Rene E. M. Toes, Cornelis J. M. Melief, Rienk Offringa, Adenoviruses Activate Human Dendritic Cells without Polarization toward a T-Helper Type 1-Inducing Subset Journal of Virology. ,vol. 73, pp. 10245- 10253 ,(1999) , 10.1128/JVI.73.12.10245-10253.1999